Hyperhomocysteinemia is a widely recognized, although not yet entirely understood, risk factor for cardiovascular disease. Particularly, the complex relationships between age, hyperhomocysteinemia, predisposing genetic factors and peripheral vascular diseases have not been fully evaluated. Our contribution to this issue is a retrospective analysis of a large series of patients with peripheral arterial, venous and lymphatic disease, and of their blood relatives, with special reference to homocysteine plasma levels, age and methylenetetrahydrofolate reductase (MTHFR) polymorphisms. Serum homocysteine was measured in 477 patients (286 males, 191 females, age range 19-78 years) with various vascular clinical conditions: postphlebitic syndrome (46) recurrent venous ulcers (78), arterial diseases (101) primary lymphoedema (87), secondary lymphoedema (161) and outlet thoracic syndrome (4), and in 50 normal controls. A MTHFR study for polymorphisms was carried on in the subjects with homocysteine values exceeding 15 mol/L. Serum homocysteine determination and MTHFR polymorphism studies were performed also in 1430 healthy blood related relatives (mainly siblings, descendents and sibling descendents) of the subjects with hyperhomocysteinemia and MTHFR polymorphisms. We found MTHFR polymorphisms in 20% of controls and in 69.3%, 69.5% and 53.8% of hyperhomocysteinemic subjects with arterial diseases, postphlebitic syndrome and venous ulcers, respectively. As expected, the percentage of hyperhomocysteinemia in patients with secondary lymphoedema and with thoracic outlet syndrome did not show significant differences compared to the control group. A MTHFR polymorphism was found in 116 out of the 214 hyperhomocysteinemic patients, i.e., in the 54% of the overall patient population with hyperhomocysteinemia (214 patients). Interestingly 750 (52%) out of the 1430 blood relatives of the 116 patients with hyperhomocysteinemia and MTHFR polymorphisms showed at least one polymorphism in MTHFR gene. In this latter group of 750 healthy blood-related relatives bearing a MTHFR polymorphism the finding of hyperhomocysteinemia increased according to the age class from 1.6% in the age range <40 years up to 54.9% in the age range >60 years. The present study demonstrate that patients with peripheral arterial disease, post-phlebitic syndrome, venous ulcers and primary lymphoedema show a significantly higher incidence of hyperhomocysteinemia compared to controls, and adds further evidence to the causative role of hyperhomocysteinemia in the development of both arterial and venous disease. Moreover our data indicate a possible causative role of hyperhomocysteinemia in primary lymphoedema. In more than 50% of our hyperhomocysteinemic patients a polymorphism of MTHFR (C677T and/or A1298C) was detected. In subjects with these polymorphisms the frequency of hyperhomocysteinemia increases with age. We observed a quite similar frequency of the two polymorphisms in the studied population and therefore claim for the need to study both C677T and A1298C mutations in hyperhomocysteinemic patients.
Introduction
The possible role of homocysteine high levels as a risk factor for vascular disease was described for the first time more than forty years ago, 1, 2 and in the following decades a large amount of evidence has demonstrated that even mild increases in homocysteinemia are associated with an increased risk of cardiovascular diseases 3, 4 including venous thromboembolic disease. 5 Hyperhomocysteinemia is frequently associated with MTHFR polymorphisms C677T and A1298C. MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. Figure 1 summarizes homocysteine metabolism. [6] [7] [8] [9] [10] [11] [12] [13] Figure 2 shows the pathophysiologic mechanism(s) of hyperhomocysteinemia-induced vascular damage. [14] [15] [16] [17] [18] In the last few years, however, the causative role of hyperhomocysteinemia in cardiovascular disease has been questioned mainly based on the reports that failed to demonstrate a clinical benefit after lowering homocysteinemia levels with vitamins B6, B12 and folate. [19] [20] [21] Particularly, it has been pointed out that treatment with homocysteine lowering agents, i.e. folic acid and B6 and B12 vitamins, over prolonged times, does not reduce the incidence of cardiovascular adverse effects, 19 although it has been reported that folate, vitamin B12 intake is associated with a reduction of the risk of ischemic stroke. 22, 23 Therefore further studies have been advocated to address this issue. 24 In order to understand the relationships between homocysteinemia and vascular disease we made a retrospective analysis of the patients who were referred to vascular disease rehabilitation program of our institute for peripheral arterial, venous and lymphatic disorders, paying special attention to homocysteine blood levels, MTHFR polymorphisms and age. The influence of MTHFR polymorphisms on homocysteine blood levels was also studied in the available healthy blood related relatives of hyperhomocysteinemic subjects with MTHFR polymorphisms.
Materials and Methods
A general description of the study is reported in Figure 3 . Briefly, serum concentration of homocysteine was measured in 477 consecutive patients (286 males, 191 females, mean age 56. 5 Homocysteine plasma determination and MTHFR polymorphism studies were performed also on 1430 healthy blood related relatives (mainly, siblings, descendents and sibling descendents) of the subjects with hyperhomocysteinemia and MTHFR polymorphisms.
Results

Patients
Hyperhomocysteinemia was found in 20% of controls and in 69.3%, 69.5% and 53.8 % of subjects with arterial diseases, postphlebitic syndrome and venous ulcers, respectively ( Table 1) . As expected, the percentage of hyperhomocysteinemia in patients with secondary lymphoedema and with thoracic outlet syndrome did not show significant differences compared to the control group (Table 1) . At least one MTHFR polymorphism was found in 116 out of the 214 hyperhomocysteinemic patients i.e. in the 54% of the overall patient population with hyperhomocysteinemia ( Table 2 ).
Blood related relatives of hyperhomocysteinemic patients bearing a methylenetetrahydrofolate reductase polymorphism
In 750 (52%) out of the 1430 blood relatives of the 116 patients with hyperhomocysteinemia and MTHFR polymorphisms at least one polymorphism in MTHFR gene was found. In this group of 750 asymptomatic subjects bearing a MTHFR polymorphism the frequency of the finding of hyperhomocysteinemia increased according to the age class from 1.6% in the age range <40 years up to 54.9% in the age range >60 years (Table 3) . C677T polymorphism-associated hyperhomocysteinemia did not significantly differ from A1298C-induced hyperhomocysteinemia either in frequency or in hyperhomocys- (Table 4) . Moreover, the association of the two polymorphisms in the same subject did not result either in an earlier appearance of hyperhomocysteinemia or in higher homocysteinemia levels. From a clinical point of view our findings indicate a quite similar frequency of the two polymorphisms in the studied population and therefore the need to study both C677T and A1298C mutations in hyperhomocysteinemic patients (Table 4) .
Discussion and Conclusions
Despite some uncertainity due to the limited number of control subjects the present study shows a far higher incidence of hyperhomocysteinemia in patients with peripheral artery disease, post-phlebitic syndrome, venous ulcers and primary lymphoedema compared to controls, therefore adding further evidence to the causative role of hyperhomocysteinemia in the development of both peripheral thrombotic arterial and venous disease and of primary lymphoedema. The patients with primary lymphoedema recruited in the present study had no evidence of other vascular disease.
In more than 50% of our hyperhomocysteinemic patients a polymorphism of MTHFR (C677T and/or A1298C) was detected. It has been also observed that in subjects with MTHFR C677T and/or A1298C polymorphism the frequency of hyperhomocysteinemia increases with age. This latter finding is especially unexpected taking into account that genetic disorders usually, although not always, produce clinically evident disorders in the first decades of life. This could possibly be explained by an age related reduction of the defences against oxidative stress.
Another interesting observation is that C677T polymorphism-associated hyperhomocysteinemia did not significantly differ from A1298C-induced hyperhomocysteinemia either in frequency or in severity. Moreover, surprisingly, the association of the two polymorphisms in the same subject is not associated either with an earlier appearance of hyperhomocysteinemia or with higher homocysteinemia levels. The very similar frequency of the C677T and A1298C polymorphisms in the patient population implies the need to study both C677T and A1298C mutations in hyperhomocysteinemic patients. Particularly, it is known that in southern Europe, and especially in Italy, the prevalence of C677T homozygous polymorphism is quite higher compared with northern and central Europe. 25 Finally, at authors' knowledge this is the first report indicating a possible causative role of hyperhomocysteinemia in primary lymphoedema. Hyperhomocysteinemic subjects were significantly (P<0.001 at Chi-square test) more frequent in the groups of subjects with arterial diseases, postphlebitic syndrome, venous ulcers and primary lymphoedema compared to controls. C677T eterozygous+A1298C homozygous  6  3  3  5  5  2  19 subjects  C677T homozygous+A1298C eterozygous  0  0  2  1  1  0  12 subjects  C677T homozygous+A1298C homozygous  2  2  1  1  3  1  2 subjects The first three columns refer to the degree of hyperhomocysteinemia. The last three columns illustrate the associated vascular disease. The frequency of hyperhomocysteinemic subjects among age groups resulted always highly significant (P<0.001 at Chi-square test). Notice that in 38 cases a double polymorphism was found. 
